

Special Issue

Advances in the Molecular Biology of Sarcoma and Drug Development

Message from the Guest Editors

Sarcomas are a diverse group of cancers arising from connective tissues, presenting significant challenges in drug development due to their rarity and heterogeneity. Traditional treatments have primarily involved surgery, radiation, and chemotherapy. Although the outcome and survival rate for some sarcoma subtypes have improved over time, the current treatment regimens remain efficaciously limited. Recurrent and metastatic diseases remain a major obstacle in clinic. Recent advances in understanding the genetic and epigenetic alterations of sarcomas and the associated signaling pathways hold promise for precise diagnosis and drug development. In this Special Issue, experts in this field will review and discuss the advances in the molecular biology of sarcoma, drug development, and personalized medicine.

Guest Editors

Prof. Dr. Francis Hornicek

Department of Orthopedic Surgery, University of Miami Leonard M. Miller School of Medicine, Miami, FL, USA

Prof. Dr. Zhenfeng Duan

Department of Orthopaedics, University of Miami, Miami, FL 33136, USA

Deadline for manuscript submissions

31 December 2025



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/232756

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)